Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
Recommended Working Concentration: 0.05-1 μg/ml
Summary
Specifications
Antibody Isotype
IgG
Immunogen
Omalizumab
Conjugate
Unconjugated
Applications
Application Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Recommended Working Concentration: 0.05-1 μg/ml
General Notes
Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Omalizumab with trade name Xolair, is an FDA-approved drug for the treatment of moderate to severe persistent asthma in adults and adolescents (12 years of age and above). It is a recombinant humanized monoclonal antibody. It selectively binds to human immunoglobulin E (IgE). Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils.
Target
Alternative Names
Rabbit polyclonal antibody to Xolair; Omalizumab; Xolair
Citations
Publication ()
Have you cited CABT-ZB270 in a publication? Let us know and earn a reward for your research.
My Review for Rabbit Anti-Omalizumab polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
